CD4 and lymphoma: The resulting third-party HSC-iNKT (3rdHSC-iNKT) cells closely resembled peripheral blood-derived endogenous CD4− iNKT cells and displayed anti-GvHD activity while preserving GvL effects in preclinical models of leukemia and lymphoma (Figures 2, 3, 4, 5, 6, and S2–S5).